Ovagen
Ovagen — reagent for research use (RUO).
Sizes and prices: 20 mg $1,750 MXN ($88 MXN per mg).
Buy Ovagen in Mexico: order online with nationwide shipping in 1-4 business days depending on zone and tracking number. Prices in Mexican pesos. Material for research use only.
Ovagen is also searched as: Peptido EDL, EDL peptide.
Identity and composition
Ovagen is the commercial and research name of the synthetic tripeptide Glu-Asp-Leu (EDL), belonging to the family of short-peptide "bioregulators" associated with V. Khavinson. It is marketed for laboratory research. Product for research use.
Its chemical identity is confirmed in PubChem (CID 444128):
- Molecular formula: C15H25N3O8
- Molecular weight: 375.37 g/mol
- Sequence: Glu-Asp-Leu (EDL); L-glutamyl-L-aspartyl-L-leucine
- Identifiers: PubChem CID 444128; CHEBI:137252
No assigned CAS number was found in PubChem or in regulatory sources, so this datum is omitted. Among its synonyms are EDL, Glu-Asp-Leu and L-glutamyl-L-aspartyl-L-leucine.
Mechanism of action
The proposed mechanism for Ovagen is described only at the class level, not specifically for EDL. The peer-reviewed literature on Khavinson's short peptides proposes that these di-, tri-, and tetrapeptides can penetrate cell and nuclear membranes and interact with DNA and histones, epigenetically modulating gene expression, methylation, and cell differentiation (Khavinson et al., Stem Cell Rev Rep 2020; PMID:31808038).
It is important to clarify that this review does not mention EDL/Glu-Asp-Leu, nor Ovagen, nor the liver; it refers to the tetrapeptide AEDL for pulmonary and pancreatic differentiation. It is cited only for the general mechanism of bioregulation, not for any hepatic claim.
No peer-reviewed source was located that describes a specific molecular target, receptor, or hepatic mechanism for EDL/Ovagen. The claims of "hepatic tropism," "hepatocyte regeneration," or of PEPT1/PEPT2 transporters appear only in vendor material and blogs, not in indexed literature, and must be treated as unverified commercial material.
Pharmacokinetics
No citable pharmacokinetic data were found for EDL/Ovagen. There is no published information on half-life, absorption, distribution or clearance in verifiable sources. For transparency: any numerical pharmacokinetic value circulating in commercial material lacks support in indexed literature and is not reproduced here.
Scientific evidence
The evidence on EDL/Ovagen is very limited and, at best, preclinical. No registered human clinical trials on ClinicalTrials.gov, nor primary studies indexed in PubMed, were located that link the tripeptide Glu-Asp-Leu with hepatic regeneration, hepatocyte function or gastrointestinal epithelium; those indications are claimed only by commercial vendors.
The peer-reviewed literature on the broader class of Khavinson short peptides describes tissue-specific effects on gene expression and cell differentiation (Khavinson et al., Stem Cell Rev Rep 2020; PMID:31808038), but does not corroborate a hepatic role for EDL. Consequently, any positioning as a "hepatic bioregulator" should be considered unverified marketing rather than established science. General confidence level: low.
Research applications
Product for research use.
It may be of interest for research:
- Exploratory in vitro and preclinical studies on short peptides and epigenetic bioregulation at the class level.
- Comparative work within the Khavinson family of peptides (characterization, handling, physicochemical analysis).
- Chemical identity verification and reference assays using the constants confirmed in PubChem.
Not applicable / out of scope:
- Any use in humans or animals for therapeutic, diagnostic, or supplementation purposes.
- Applications that presuppose a hepatic, hepatocyte-regeneration or gastrointestinal effect, since there is no indexed evidence to support it.
- Extrapolating to EDL the published data of the tetrapeptide AEDL (a distinct peptide).
Research protocols
No dosing protocols for EDL/Ovagen were found in primary studies indexed in PubMed, nor phases or indications registered on ClinicalTrials.gov. For that reason, no numerical study doses are reported.
Any experimental design with this compound must be based on internal protocols validated by the investigator's own laboratory, with adequate controls and reference documentation, understanding that there is no established dose range in the literature for this specific tripeptide.
Reconstitution
As a standard general laboratory handling guide for lyophilized peptides: reconstitution is usually carried out with bacteriostatic water (water for injection with approximately 0.9% benzyl alcohol as preservative), added slowly along the vial wall onto the powder.
- Avoid injecting the diluent directly onto the pellet; let it dissolve without vigorous agitation (gently swirl the vial, do not shake it).
- The diluent volume is chosen according to the working concentration desired for your assays.
- Work with aseptic technique.
These instructions are for general laboratory handling and do not constitute a clinical protocol or a recommendation for use in living organisms.
Stability and storage
As a standard for handling peptides:
- Lyophilized (powder): is the most stable form. It is usually stored refrigerated and, for prolonged storage, frozen, protected from light and humidity.
- Reconstituted (in solution): less stable; it is kept refrigerated and used within a short window, avoiding repeated freeze-thaw cycles.
There are no published stability data specific to EDL/Ovagen; these guidelines are general laboratory handling practices. Document lot, reconstitution date, and storage conditions for experimental traceability.
Safety profile
No documented safety, toxicology or adverse-event data were found for EDL/Ovagen in peer-reviewed or regulatory sources. The absence of documented harm is not equivalent to evidence of safety.
The compound is sold exclusively for research use and does not have an established human safety profile. No formal contraindications are available because there is no published toxicological characterization. It must be handled with the usual precautions for uncharacterized laboratory reagents and never administered to humans or animals.
Comparative context
EDL belongs to the same family of short Khavinson "bioregulator" peptides as other well-known compounds:
- Epitalon (Ala-Glu-Asp-Gly): tetrapeptide, associated with the pineal context.
- Vilon (Lys-Glu): dipeptide.
- Pinealon / EDR (Glu-Asp-Arg): tripeptide.
- AEDL (Ala-Glu-Asp-Leu): a related tetrapeptide, reported in the literature for pulmonary differentiation.
A key warning to avoid confusion: the peer-reviewed data on pulmonary and pancreatic differentiation correspond to the AEDL tetrapeptide, not the EDL tripeptide marketed as Ovagen. They are distinct molecules and must not be treated as interchangeable. In addition, there are no peer-reviewed head-to-head comparisons that support claims of relative efficacy between these peptides for specific organs.
History and development
Ovagen is the commercial and research name of the synthetic tripeptide Glu-Asp-Leu (EDL), which emerged within the line of "short bioregulatory peptides" associated with the researcher V. Khavinson. This scientific program has proposed, at the class level, that certain di-, tri-, and tetrapeptides can influence gene expression and cell differentiation via epigenetic pathways.
Its chemical identity is registered in PubChem (CID 444128) and CHEBI (137252). However, specific research on EDL is very scarce: no indexed primary studies characterizing its biological activity were located, so its documented development is essentially limited to its chemical definition and its membership in the Khavinson peptide family.
FAQ
What is Ovagen and what does it contain?
Ovagen is the trade name of the synthetic tripeptide Glu-Asp-Leu (EDL), a short peptide of the Khavinson family of bioregulators. Its identity is confirmed in PubChem (CID 444128): formula C15H25N3O8 and molecular weight 375.37 g/mol. It is sold as a product for research use; not for clinical use.
Does Ovagen work to regenerate the liver or hepatocytes?
There is no indexed evidence to support it. No primary studies were found in PubMed linking EDL/Ovagen to hepatic regeneration or hepatocyte function. That positioning appears only in commercial material and must be treated as unverified, not as established science.
What is the difference between EDL (Ovagen) and AEDL?
They are different molecules: EDL is a tripeptide (Glu-Asp-Leu) and AEDL is a tetrapeptide (Ala-Glu-Asp-Leu). The peer-reviewed data on pulmonary differentiation correspond to AEDL, not to EDL. They must not be treated as interchangeable.
Are there dose or half-life data for Ovagen?
No. No pharmacokinetic data (half-life, absorption, clearance) or dosing protocols were located in indexed studies or on ClinicalTrials.gov. For the sake of transparency, no figures lacking support in verifiable literature are reported.
How is Ovagen reconstituted and stored?
As a general laboratory guide, lyophilized peptides are usually reconstituted with bacteriostatic water added down the wall of the vial, without shaking. The lyophilized powder is stored refrigerated or frozen; once reconstituted it is kept refrigerated and used within a short window, avoiding freeze-thaw cycles.
Is Ovagen safe?
There are no documented data on safety, toxicology or adverse events in peer-reviewed or regulatory sources. The absence of documented harm is not equivalent to evidence of safety. It is marketed only for research and has no established human safety profile.
Scientific references (2)
Peer-reviewed literature on Ovagen, with its PubMed identifier when available:
- Nephroprotective Effect of EDL Peptide at Acute Injury of Kidneys of Different Genesis (Zamorskii, et al. · Bulletin of Experimental Biology and Medicine · 2017) PMID 28744634.
- Peptides Restore Functional State of the Kidneys During Cisplatin-Induced Acute Renal Failure (Zamorskii, et al. · Bulletin of Experimental Biology and Medicine · 2015) PMID 26515176.
Full scientific profile: Ovagen in the compendium — mechanism of action, studies and technical data sheet.
See the full category catalog: Bioregulators.
Guides and articles about Ovagen
Lecturas del blog de EXOMA que la editorial asoció a este compuesto: